The global viral inactivation market was valued at USD 320.5 Million in 2016 and poised to grow at a CAGR of 12.3% between 2016 and 2021, to reach USD 573.0 Million in 2021. Viral inactivation testing is necessary by regulatory authorities for investigational new drug (IND) submission and is mainly critical in process development for biological including tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, and vaccine and therapeutics. The major drivers for the market are rapid growth in pharmaceutical and biotechnology industries and strong trend of R&D investments in the life sciences industry. An Increasing number of new drug launches, rise in chronic disease burden, and increasing government support for the pharmaceutical and biotechnology industries will also aid the growth of this market.
Over the years, the number of drug approvals in North American countries has increased from 2006 to 2015. In 2015, the FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or a new therapeutic biologic under Biologics License Applications (BLAs) as compared to 22 novel drugs approved in 2006. The increasing number of drug approvals will boost the viral inactivation market.
According to OECD estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain (3,025 biotechnology companies), and France (1,481 biotechnology companies). Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Viral inactivation is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the viral inactivation market.
Complete report, on Viral Inactivation Market spread across 154 pages, with 72 tables and 70 figures is now available at http://www.rnrmarketresearch.com/viral-inactivation-market-by-product-kits-reagents-systems-services-application-stem-cell-blood-tissue-cell-gene-therapy-method-solvent-detergent-pasteurization-end-user-pharmaceutical-and-biotec-st-to-2021-market-report.html
This report segments the global viral inactivation market is segmented based on method, product, application, end user, and geography. The method segments included in the report are solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light.
The product segments included in the report are kits and reagents, services, and viral inactivation systems and accessories.
The major players in the viral inactivation market include Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).
The geographic segments included in this report are Asia, Europe, North America and the Rest of the World (RoW). North America is further divided into Canada and the U.S. Asia is further divided in to China, Japan, India, and Rest of Asia.
Get Sample Copy of this Report now at http://www.rnrmarketresearch.com/contacts/request-sample?rname=608003
The report provides qualitative insights on key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and growth rates of each subsegment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the viral inactivation market. The competitive landscape covers the growth strategies adopted by industry players over the last three years. It also includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.
The report provides insights on the following:
Product Development/Innovation: Product portfolios of top players in the viral inactivation market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the viral inactivation market
Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the viral inactivation market
Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various viral inactivation products across geographies
Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the viral inactivation market
Virus Filtration Market by Product (Kits & Reagents, Systems, Services), Application (Biologics (Vaccine & Therapeutics, Blood, Tissues, Stem Cells), Devices, Air, Water Purification), End User (Biopharmaceutical, CROs, Research) - Global Forecast to 2020. Is now available at RnrMarketresearch.com the companies profiled in this report are Merck Kgaa, General Electric Company, Thermo Fisher Scientific, Inc. Lonza Group Ltd., Pall Corporation, Charles River Laboratories International, Inc., Sigma-Aldrich Corporation, Sartorius AG, Asahi Kasei Medical Co., Ltd and Wuxi Pharmatech (Cayman) Inc. The report is available at http://www.rnrmarketresearch.com/virus-filtration-market-by-product-kits-reagents-systems-services-application-biologics-vaccine-therapeutics-blood-tissues-stem-cells-devices-air-water-purification-end-user-biopharmaceutical-c-st-to-2020-market-report.html